Read More General business news Abbott (NYSE: ABT) showcases four HRS 2026 trials as cardiac rhythm market competition intensifies Abbott has fresh arrhythmia data, but its stock sits near yearly lows. Can cardiac innovation reset investor confidence? byVenkateshApril 26, 2026